1. DiFiglia M, Sapp E, Chase KO, et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997;277:1990–1993.
2. Gutekunst CA, Li SH, Yi H, et al. Nuclear and neuropil aggregates in Huntington's disease: Relationship to neuropathology. J Neurosci 1999;19:2522–2534.
3. Sapp E, Kegel KB, Aronin N, et al. Early and progressive accumulation of reactive microglia in the Huntington disease brain. J Neuropathol Exp Neurol 2001;60:161–172.
4. Singhrao SK, Neal JW, Morgan BP, et al. Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease. Exp Neurol 1999;159:362–376.
5. Bruyn GW. Huntington's chorea. Historical, clinical and laboratory synopsis. In Vinken PJ and Bruyn GW (eds). Handbook of Clinical Neurology, Vol. 6. Amsterdam: Elsevier, 1968, pp. 298–378.
6. Bruyn G, Bots G, and Dom R. Huntington's chorea: Current neuropathological status. Adv Neurol 1979;23:83–93.
7. Lange H, Thorner G, Hopf A, et al. Morphometric studies of the neuropathological changes in choreatic diseases. J Neurol Sci 1976;28:401–425.
8. Tai YF, Pavese N, Gerhard A, et al. Microglial activation in presymptomatic Huntington's disease gene carriers. Brain 2007;130(pt 7):1759–1766.
9. Pavese N, Gerhard A, Tai YF, et al. Microglial activation correlates with severity in Huntington disease: A clinical and PET study. Neurology 2006;66(11):1638–1643.
10. Myers RH, Vonsattel JP, Paskevich PA, et al. Decreased neuronal and increased oligodendroglial densities in Huntington's disease caudate nucleus. J Neuropathol Exp Neurol 1991;50:729–742.
11. Vonsattel JP, Myers RH, Stevens TJ, et al. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985;44:559–577.
12. Roos RA, Pruyt JF, de Vries J, et al. Neuronal distribution in the putamen in Huntington's disease. J Neurol Neurosurg Psychiatry 1985;48:422–425.
13. Gomez-Tortosa E, MacDonald ME, Friend JC, et al. Quantitative neuropathological changes in presymptomatic Huntington's disease. Ann Neurol 2001;49:29–34.
14. Aylward EH, Codori AM, Rosenblatt A, et al. Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease. Mov Disord 2000;15:552–560.
15. Aylward EH, Codori AM, Barta PE, et al. Basal ganglia volume and proximity to onset in presymptomatic Huntington disease. Arch Neurol 1996;53:1293–1296.
16. Thieben MJ, Duggins AJ, Good CD, et al. The distribution of structural neuropathology in pre-clinical Huntington's disease. Brain 2002;125(pt 8):1815–1828.
17. Furtado S, Suchowersky O, Rewcastle B, et al. Relationship between trinucleotide repeats and neuropathological changes in Huntington's disease. Ann Neurol 1996;39:132–136.
18. Penney JB Jr, Vonsattel JP, MacDonald ME, et al. CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol 1997;41:689–692.
19. Rosas HD, Goodman J, Chen YI, et al. Striatal volume loss in HD as measured by MRI and the influence of CAG repeat. Neurology 2001;57:1025–1028.
20. Dom R, Baro F, and Brucher JM. A cytometric study of the putamen in different types of Huntington's chorea. Adv Neurol 1973;1:369–385.
21. Kuhn A, Goldstein DR, Hodges A, et al. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum Mol Genet 2007; 16(15):1845–1861.
22. Perry TL, Hansen S, and Kloster M. Huntington's chorea. Deficiency of gamma-aminobutyric acid in brain. N Engl J Med 1973;288:337–342.
23. Bird ED and Iversen LL. Huntington's chorea. Post-mortem measurement of glutamic acid decarboxylase, choline acetyltransferase and dopamine
in basal ganglia. Brain 1974;97:457–472.
24. Spokes EGS. Neurochemical alterations in Huntington's chorea. A study of post-mortem brain tissue. Brain 1980;103:179–210.
25. Carter CJ. Reduced GABA transaminase activity in the Huntington's disease putamen. Neurosci Lett 1984;48:339–342.
26. Reynolds GP and Pearson SJ. Decreased glutamic acid and increased 5-hydroxytryptamine in Huntington's disease brain. Neurosci Lett 1987;78:233–238.
27. Marshall P, Landis D, Zalneraitis E. Immunocytochemical studies of substance P and leucine-enkephalin in Huntington's disease. Brain Res 1983;289:11–26.
28. Goto S, Hirano A, and Rojas-Corona RR. An immunohistochemical investigation of the human neostriatum in Huntington's disease. Ann Neurol 1989;25:298–304.
29. Ferrante R, Kowall N, and Richardson E Jr. Immunocytochemical localization of calcium binding protein in normal and Huntington's disease striatum. J Neuropathol Exp Neurol 1988;47:352.
30. Seto-Ohshima A, Emson PC, Lawson E, et al. Loss of matrix calcium-binding protein-containing neurons in Huntington's disease. Lancet 1988;i:1252–1255.
31. Augood SJ, Faull RL, and Emson PC. Dopamine
D1 and D2 receptor gene expression in the striatum in Huntington's disease. Ann Neurol 1997;42:215–221.
32. Martinez-Mir MI, Pollard H, Moreau J, et al. Loss of striatal histamine H2 receptors in Huntington's chorea but not in Parkinson's disease: comparison with animal models. Synapse 1993;15:209–220.
33. Joyce JN, Lexow N, Bird E, et al. Organization of dopamine
D1 and D2 receptors in human striatum: Receptor autoradiographic studies in Huntington's disease and schizophrenia. Synapse 1988;2:546–557.
34. Richfield EK, O'Brien CF, Eskin T, et al. Heterogeneous dopamine
receptor changes in early and late Huntington's disease. Neurosci Lett 1991;132:121–126.
35. Richfield EK and Herkenham M. Selective vulnerability in Huntington's disease: Preferential loss of cannabinoid receptors in lateral globus pallidus. Ann Neurol 1994;36:577–584.
36. Martinez-Mir MI, Probst A, and Palacios JM. Adenosine
A2 receptors: Selective localization in the human basal ganglia and alterations with disease. Neuroscience 1991;42:697–706.
37. Gerfen C. The neostriatal mosaic: Multiple levels of compartmental organization in the basal ganglia. Annu Rev Neurosci 1992;15:285–320.
38. Kanazawa I, Bird E, O'Connell R, et al. Evidence for the decrease in substance P content of substantia nigra in Huntington's chorea. Brain Res 1977;120:387–392.
39. Gale J, Bird E, Spokes E, et al. Human brain substance P: Distribution in controls and Huntington's chorea. J Neurochem 1978;30:633–634.
40. Emson P, Arregui A, Clement-Jones V, et al. Regional distribution of met-enkephalin and substance P immunoreactivity in normal human brain and in Huntington's disease. Brain Res 1980;199:147–160.
41. Grafe MR, Forno LS, and Eng LF. Immunocytochemical studies of substance P and Met-enkephalin in the basal ganglia and substantia nigra in Huntington's, Parkinson's and Alzheimer's diseases. J Neuropathol Exp Neurol 1985;44:47–59.
42. Waters CM, Peck R, Rossor M, et al. Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson's disease and Huntington's chorea. Neuroscience 1988;25:419–438.
43. Beal MF, Ellison DW, Mazurek MF, et al. A detailed examination of substance P in pathologically graded cases of Huntington's disease. J Neurol Sci 1988;84:51–61.
44. Glass M, Dragunow M, and Faull RL. The pattern of neurodegeneration in Huntington's disease: A comparative study of cannabinoid, dopamine
and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 2000;97:505–519.
45. Cha JH, Frey AS, Alsdorf SA, et al. Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. Philos Trans R Soc Lond B Biol Sci 1999;354:981–989.
46. Reiner A, Albin RL, Anderson KD, et al. Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci U S A 1988;85:5733–5737.
47. Albin RL, Young AB, Penney JB, et al. Abnormalities of striatal projection neurons and N-methyl-d-aspartate receptors in presymptomatic Huntington's disease. N Engl J Med 1990;322:1293–1298.
48. Storey E and Beal MF. Neurochemical substrates of rigidity and chorea in Huntington's disease. Brain 1993;116(pt 5):1201–1222.
49. Crossman AR. Primate models of dyskinesia: The experimental approach to the study of basal ganglia-related involuntary movement disorders. Neuroscience 1987;21:1–40.
50. Albin R, Young A, and Penney J. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989;12:366–375.
51. DeLong M. Primate models of movement disorders of basal ganglia origin. Trends Neurosci 1990;13:281–285.
52. Crossman A, Mitchell I, Sambrook M, et al. Chorea and myoclonus in the monkey induced by gamma-aminobutyric acid antagonism in the lentiform complex. Brain 1988;111:1211–1233.
53. Kowall N, Ferrante R, and Martin J. Patterns of cell loss in Huntington's disease. Trends Neurosci 1987;10:24–29.
54. Ferrante R, Kowall N, Martin J, et al. Substance P-containing striatal neurons in Huntington's disease. Exp Neurol 1987;46:375.
55. Ferrante RJ, Beal MF, Kowall NW, et al. Sparing of acetylcholinesterase-containing striatal neurons in Huntington's disease. Brain Res 1987;411:162–166.
56. Cicchetti F, Gould PV, and Parent A. Sparing of striatal neurons coexpressing calretinin and substance P (NK1) receptor in Huntington's disease. Brain Res 1996;730:232–237.
57. Beal M, Kowall N, Ellison D, et al. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 1986;321:168–171.
58. Aronin N, Cooper PE, Lorenz LJ, et al. Somatostatin is increased in the basal ganglia in Huntington's disease. Ann of Neurol 1983;13:519–526.
59. Albin RL, Reiner A, Anderson KD, et al. Striatal and nigral neuron subpopulations in rigid Huntington's disease: Implications for the functional anatomy of chorea and rigidity akinesia. Ann Neurol 1990;27:357–365.
60. Ferrante RJ, Kowall NW, Beal MF, et al. Morphologic and histo-chemical characteristics of a spared subset of striatal neurons in Huntington's disease. J Neuropathol Exp Neurol 1987;46:12–27.
61. Ferrante RJ, Kowall NW, Beal MF, et al. Selective sparing of a class of striatal neurons in Huntington's disease. Science 1985;230:561–563.
62. Dawbarn D, De Quidt ME, and Emson PC. Survival of basal ganglia neuropeptide Y-somatostatin neurones in Huntington's disease. Brain Res 1985;340:251–260.
63. McGeer E and McGeer P. Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acids. Nature 1976;263:517–519.
64. Hersch S, Gutekunst C-A, Rees H, et al. Distribution of m1–4 muscarinic receptor proteins in the rat striatum. Light and electron microscopic immunocytochemistry using subtype specific antibodies. J Neurosci 1994;14:3351–3363.
65. Graveland GA, Williams RS, and DiFiglia M. Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease. Science 1985;227:770–773.
66. Ferrante RJ, Kowall NW, and Richardson EP Jr. Proliferative and degenerative changes in striatal spiny neurons in Huntington's disease: A combined study using the section-Golgi method and calbindin D28k immunocytochemistry. J Neurosci 1991;11:3877–3887.
67. Guidetti P, Charles V, Chen EY, et al. Early degenerative changes in transgenic mice expressing mutant huntingtin involve dendritic abnormalities but no impairment of mitochondrial energy production. Exp Neurol 2001;169:340–350.
68. Laforet GA, Sapp E, Chase K, et al. Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease. J Neurosci 2001;21:9112–9123.
69. Klapstein GJ, Fisher RS, Zanjani H, et al. Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice. J Neurophysiol 2001;86:2667–2677.
70. Butterworth NJ, Williams L, Bullock JY, et al. Trinucleotide (CAG) repeat length is positively correlated with the degree of DNA fragmentation in Huntington's disease striatum. Neuroscience 1998;87:49–53.
71. Portera-Cailliau C, Hedreen JC, Price DL, et al. Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models.J Neurosci 1995;15(5 pt 2):3775–3787.
72. Kiechle T, Dedeoglu A, Kubilus J, et al. Cytochrome C and caspase-9 expression in Huntington's disease. Neuromol Med 2002;1:183–195.
73. Dikranian K, Ishimaru MJ, Tenkova T, et al. Apoptosis in the in vivo mammalian forebrain. Neurobiol Dis 2001;8:359–379.
74. Browne SE, Ferrante RJ, and Beal MF. Oxidative stress in Huntington's disease. Brain Pathol 1999;9(1):147–163.
75. Graybiel A. Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci 1990;13:244–254.
76. Ferrante RJ, Kowall NW, Richardson EP Jr, et al. Topography of enkephalin, substance P and acetylcholinesterase staining in Huntington's disease striatum. Neurosci Lett 1986;71:283–288.
77. Ferrante RJ and Kowall NW. Tyrosine hydroxylase-like immunoreactivity is distributed in the matrix compartment of normal human and Huntington's disease striatum. Brain Res 1987;416:141–146.
78. Kiyama H, Seto-Ohshima A, and Emson PC. Calbindin D28K as a marker for the degeneration of the striatonigral pathway in Huntington's disease. Brain Res 1990;525:209–214.
79. Hersch S, Ciliax B, Gutekunst C-A, et al. Electron microscopic analysis of D1 and D2 dopamine
receptor proteins in the dorsal striatum and their synaptic relationships with motor corticostriatal afferents. J Neurosci 1995;15:5222–5237.
80. Tippett LJ, Waldvogel HJ, Thomas SJ, et al. Striosomes and mood dysfunction in Huntington's disease. Brain 2007;130(pt 1):206–221.
81. Bruyn G. Neuropathological changes in Huntington's chorea. Adv Neurol 1973;1:399–403.
82. Sapp E, Ge P, Aizawa H, et al. Evidence for a preferential loss of enkephalin immunoreactivity in the external globus pallidus in low grade Huntington's disease using high resolution image analysis. Neurosci 1995;64:397–404.
83. Forno LS and Jose C. Huntington's chorea: A pathological study. Adv Neurol 1973;1:453–470.
84. Bugiani O, Tabaton M, and Cammarata S. Huntington's disease: Survival of large striatal neurons in the rigid variant. Ann Neurol 1984;15:154–156.
85. Oyanagi K, Takeda S, Takahashi H, et al. A quantitative investigation of the substantia nigra in Huntington's disease. Ann Neurol 1989;26:13–19.
86. Ferrante R, Kowall N, Richardson EJ. Neuronal and neuropil loss in the substantia nigra in Huntington's disease. J Neuropathol Exp Neurol 1989;48:380.
87. Bohnen NI, Koeppe RA, Meyer P, et al. Decreased striatal monoaminergic terminals in Huntington disease. Neurology 2000;54:1753–1759.
88. Saji M and Reis D. Delayed transneuronal death of substantia nigra neurons prevented by gamma-aminobutyric acid. Science 1987;235:66–69.
89. Dom R, Malfroid M, and Baro F. Neuropathology of Huntington's chorea. Studies of the ventrobasal complex of the thalamus. Neurology 1976;26:64–68.
90. Heinsen H, Rub U, Gangnus D, et al. Nerve cell loss in the thalamic centromedian-parafascicular complex in patients with Huntington's disease. Acta Neuropathol (Berl) 1996;91:161–168.
91. Heinsen H, Rub U, Bauer M, et al. Nerve cell loss in the thalamic mediodorsal nucleus in Huntington's disease. Acta Neuropathol (Berl) 97:613–622, 1999.
92. Kremer HP, Roos RA, Dingjan GM, et al. The hypothalamic lateral tuberal nucleus and the characteristics of neuronal loss in Huntington's disease. Neurosci Lett 1991;132:101–104.
93. Kremer HP, Roos RA, Dingjan G, et al. Atrophy of the hypothalamic lateral tuberal nucleus in Huntington's disease. J Neuropathol Exp Neurol 1990;49:371–382.
94. Petersen A, Gil J, Maat-Schieman ML, et al. Orexin loss in Huntington's disease. Hum Mol Genet 2005;14(1):39–47.
95. Alzheimer A. Über die anatomische Grunglage der Huntingtonschen Chorea und der choreatischen bewegungen Überhaupt. Neurol Zentral 1911;30:891–892.
96. Hallervorden J. Huntingtonsche chorea (chorea chronica progressiva herditaria). In Lubarsch O, et al. (eds). Handbuch der speziellen pathologischen Anatomie und Histologie. Springer: Berlin, 1957, pp. 793–822.
97. Zuccato C, Ciammola A, Rigamonti D, et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 2001;293:493–498.
98. Alexander GE, Delong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 1986;9:357–381.
99. Alexander GE, Crutcher MD, and DeLong MR. Basal gangliathalamocortical circuits: Parallel substrates for motor, oculo-motor, “prefrontal” and “limbic” functions. Prog Brain Res 1990;85:119–146.
100. Stack EC
, Dedeoglu A, Smith KM, et al. Neuroprotective effects of synaptic modulation in Huntington's disease R6/2 mice. J Neurosci 2007;27(47):12908–12915.
101. Lange HW. Quantitative changes of telencephalon, diencephalon, and mesencephalon in Huntington's chorea, postencephalic, and idiopathic Parkinson's disease. Verh Anat Ges 1981;75:923–925.
102. De la Monte SM, Vonsattel JP, and Richardson EP Jr. Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease. J Neuropathol Exp Neurol 1988;47:516–525.
103. Halliday GM, McRitchie DA, Macdonald V, et al. Regional specificity of brain atrophy in Huntington's disease. Exp Neurol 1998;154:663–672.
104. Sieradzan K, Mann DM, Dodge A. Clinical presentation and patterns of regional cerebral atrophy related to the length of trinucleotide repeat expansion in patients with adult onset Huntington's disease. Neurosci Lett 1997;225:45–48.
105. Aylward EH, Brandt J, Codori AM, et al. Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at-risk persons. Neurology 1994;44:823–828.
106. Aylward EH, Li Q, Stine OC, et al. Longitudinal change in basal ganglia volume in patients with Huntington's disease. Neurology 1997;48:394–399.
107. Rosas HD, Liu AK, Hersch S, et al. Regional and progressive thinning of the cortical ribbon in Huntington's disease. Neurology 2002;58:695–701.
108. Rosas HD, Salat DH, Lee SY, et al.Complexity and heterogeneity: What drives the ever-changing brain in Huntington's disease? Ann N Y Acad Sci 2008;1147:196–205.
109. Hersch S, Gutekunst C-A, Rosenfeld V, et al. A Quantitative morphometric study of the cerebral cortex in Huntington's disease. World Fed Neurol (Abs), 1991.
110. Sotrel A, Paskevich PA, Kiely DK, et al. Morphometric analysis of the prefrontal cortex in Huntington's disease. Neurology 1991;41:1117–1123.
111. Hedreen JC, Peyser CE, Folstein SE, et al. Neuronal loss in layers V and VI of cerebral cortex in Huntington's disease. Neurosci Lett 1991;133:257–261.
112. Rajkowska G, Selemon L, and Goldman-Rakic P. Morphometric evidence for prefrontal cellular atrophy in advanced Huntington's disease. Soc Neurosci Abstr 1993;19:838.
113. Braak H and Braak E. Allocortical involvement in Huntington's disease. Neuropathol Appl Neurobiol 1992;18:539–547.
114. Braak H, Del Tredici K, Bohl J, et al. Pathological changes in the parahippocampal region in select non-Alzheimer's dementias. Ann N Y Acad Sci 2000;911:221–239.
115. Rosas HD, Salat DH, Lee SY, et al. Cerebral cortex and the clinical expression of Huntington's disease: Complexity and heterogeneity. Brain 2008;131(pt 4):1057–1068.
116. Vonsattel JP, Keller C, and Pilar Amaya MD. Neuropathology of Huntington's disease. Handb Clin Neurol 2008;89:599–618.
117. Rosas HD, Tuch DS, Hevelone ND, et al. Diffusion tensor imaging in presymptomatic and early Huntington's disease: Selective white matter pathology and its relationship to clinical measures. Mov Disord 2006;21(9):1317–1325.
118. Kloppel S, Draganski B, Golding CV, et l. White matter connections reflect changes in voluntary-guided saccades in pre-symptomatic Huntington's disease. Brain 2008;131(pt 1):196–204.
119. Reading SA, Yassa MA, Bakker A, et al. Regional white matter change in pre-symptomatic Huntington's disease: A diffusion tensor imaging study. Psychiatry Res 2005;140(1):55–62.
120. Weaver KE, Richards TL, Liang O, et al. Longitudinal diffusion tensor imaging in Huntington's Disease. Exp Neurol 2009;216(2):525–529.
121. Clark VP, Lai S, Deckel AW. Altered functional MRI responses in Huntington's disease. Neuroreport 2002;13:703–706.
122. Aron AR, Schlaghecken F, Fletcher PC, et al. Inhibition of subliminally primed responses is mediated by the caudate and thalamus: Evidence from functional MRI and Huntington's disease. Brain 2003;126(pt 3):713–723.
123. Backman L, Robins-Wahlin TB, Lundin A, et al. Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes. Brain 1997;120(pt 12):2207–2217.
124. Feigin A, Leenders KL, Moeller JR, et al. Metabolic network abnormalities in early Huntington's disease: An [(18)F]FDG PET study. J Nucl Med 2001;42:1591–1595.
125. Antonini A, Leenders KL, Spiegel R, et al. Striatal glucose metabolism and dopamine
D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain 1996;119(pt 6):2085–2095.
126. Ginovart N, Lundin A, Farde L, et al. PET study of the pre and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. Brain 1997;120(pt 3):503–514.
127. McCaughey W. The pathologic spectrum of Huntington's chorea. J Nerv Ment Dis 1961;133:91–103.
128. Byers RK, Gilles FH, Fung C. Huntington's disease in children. Neuropathologic study of four cases. Neurology 1973;23:561–569.
129. Roizin L, Kaufman M, Wilson N, et al. Neuropathologic observations in Huntington's chorea. In Zimmerman H (ed). Progress in Neuropathology. New York: Grune & Stratton, 1976, pp. 447–488.
130. Heinsen H, Strik M, Bauer M, et al. Cortical and striatal neurone number in Huntington's disease. Acta Neuropathol 1994;88:320–333.
131. Selemon LD, Rajkowska G, and Goldman-Rakic PS. Elevated neuronal density in prefrontal area 46 in brains from schizophrenic patients: Application of a three-dimensional, stereologic counting method. J Comp Neurol 1998;392:402–412.
132. Zalneraitis EL, Landis DMA, Richardson EPJ, et al. A comparison of astrocytic structure in cerebral cortex and striatum in Huntington's disease. Neurology 1981 ;31:151(abstract).
133. Cudkowicz M, Kowall NW. Degeneration of pyramidal projection neurons in Huntington's disease cortex. Ann Neurol 1990;27:200–204.
134. Beal MF, Swartz KJ, Finn SF, et al. Amino acid and neuropeptide neurotransmitters in Huntington's disease cerebellum. Brain Res 1988;454: 393–396.
135. Mazurek MF, Beal MF, Knowlton SF, et al. Elevated concentrations of cholecystokinin and vasoactive intestinal peptide in Huntington's disease postmortem cerebral cortex. Neurology 1989;39(suppl 1):203.
136. Storey E, Kowall NW, Finn SF, et al. The cortical lesion of Huntington's disease: Further neurochemical characterization, and reproduction of some of the histological and neurochemical features by N-methyl-d-aspartate lesions of rat cortex. Ann Neurol 1992;32:526–534.
137. Sotrel A, Paskevich P, Kiely D, et al. Morphometric analysis of the prefrontal cortex in Huntington's disease. Neurology 1991;41:1117–1123.
138. Ellison DW, Beal MF, Mazurek MF, et al. Amino acid neuro-transmitter abnormalities in Huntington's disease and in the quinolinic acid animal model of Huntington's disease. Brain 1987;110:1657–1673.
139. Wagster MV, Hedreen JC, Peyser CE, et al. Selective loss of [3H]kainic acid and [3H]AMPA binding in layer VI of frontal cortex in Huntington's disease. Exp Neurol 1994;127:70–75.
140. Hassel B, Tessler S, Faull RL, et al. Glutamate uptake is reduced in prefrontal cortex in Huntington's disease. Neurochem Res 2008;33(2):232–237.
141. Mazurek MF, Garside S, Beal MF. Cortical peptide changes in Huntington's disease may be independent of striatal degeneration. Ann Neurol 1997;41:540–547.
142. Zuccato C, Marullo M, Conforti P, et al. Systematic assessment of BDNF and its receptor levels in human cortices affected by Huntington's disease. Brain Pathol 2008;18(2):225–238.
143. Smith R, Klein P, Koc-Schmitz Y, . Loss of SNAP-25 and rabphilin 3a in sensory-motor cortex in Huntington's disease. J Neurochem 2007;103(1):115–123.
144. Hodges A, Strand AD, Aragaki AK, et al. Regional and cellular gene expression changes in human Huntington's disease brain. Hum Mol Genet 2006;15(6):965–977.
145. Markham C, Knox J. Observations on Huntington's chorea in childhood. J Pediatr 1965;67:46–57.
146. Jervis G. Huntington's chorea in childhood. Arch Neurol 1963;9:50–63.
147. Rodda R. Cerebellar atrophy in Huntington's disease. J Neurol Sci 1981;50:147–157.
148. Jeste DV, Barban L, Parisi J. Reduced Purkinje cell density in Huntington's disease. Exp Neurol 1984;85:78–86.
149. McCaughey WTE. The pathologic spectrum of Huntington's chorea. J Nerv Ment Dis 1961;133:91–103.
150. Coyle J, Schwarcz R. Lesions of striatal neurons with kainic acid provides a model for Huntington's chorea. Nature 1976;263:244–246.
151. Ferrante RJ, Kowall NW, Cipolloni PB, et al. Excitotoxin lesions in primates as a model for Huntington's disease. Histopathologic and neurochemical characterization. Exp Neurol 1993;119:46–71.
152. Beal MF, Kowall NW, Ferrante RJ, et al. Quinolinic acid striatal lesions in primates as a model of Huntington's disease. Ann Neurol 1989;26:137.
153. Beal MF, Ferrante RJ, Swartz KJ, et al. Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. J Neurosci 1991;11:1649–1659.
154. Bazzett TJ, Becker JB, Kaatz KW, et al. Chronic intrastriatal dialytic administration of quinolinic acid produces selective neural degeneration. Exp Neurol 1993;120:177–185.
155. Young AB, Greenamyre JT, Hollingsworth Z, et al. NMDA receptor losses in putamen from patients with Huntington's disease. Science 1988;241: 981–983.
156. Dure LS, Young AB, Penney JB. Excitatory amino acid binding sites in the caudate nucleus and frontal cortex of Huntington's disease. Ann Neurol 1991;30:785–793.
157. Gutekunst C-A, Hersch S, Wimpey T, et al. Western blot analysis of glutamate receptor subunits in huntington's disease. Soc Neurosci, 1993.
158. Levine MS, Klapstein GJ, Koppel A, et al. Enhanced sensitivity to N-methyl-d-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. J Neurosci Res 1999;58:515–532.
159. Zeron MM, Hansson O, Chen N, et al. Increased sensitivity to N-methyl-d-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 2002;33:849–860.
160. Behrens PF, Franz P, Woodman B, et al. Impaired glutamate transport and glutamate-glutamine cycling: Downstream effects of the Huntington mutation. Brain 2002;125(pt 8):1908–1922.
161. Cepeda C, Hurst RS, Calvert CR, et al. Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. J Neurosci 2003;23:961–969.
162. McGeer EG, McGeer PL, and Singh K. Kainate-induced degeneration of neostriatal neurons: Dependency upon corticostriatal tract. Brain Res 1978;139:381–383.
163. Biziere K and Coyle JT. Effects of cortical ablation on the neurotoxicity and receptor binding of kainic acid in striatum. J Neurosci Res 1979;4:383–398.
164. Meldrum A, Dunnett SB, and Everitt BJ. Role of corticostriatal and nigrostriatal inputs in malonate-induced striatal toxicity. NeuroReport 2001;12:89–89.
165. Stack EC
, Dedeoglu A, Smith KM, et al. Neuroprotective effects of synaptic modulation in Huntington's disease R6/2 mice. J Neurosci 2007;27(47):12908–12915.
166. Reynolds DS, Carter RJ, and Morton AJ. Dopamine
modulates the susceptibility of striatal neurons to 3-nitropropionic acid in the rat model of Huntington's disease. J Neurosci 1998;18(23):10116–10127.
167. Ferrante RJ, Andreassen OA, Dedeoglu A, et al. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J Neurosci 2002;22:1592–1599.
168. Schiefer J, Landwehrmeyer GB, Luesse HG, et al. Riluzole
prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease. Mov Disord 2002;17:748–757.
169. Schilling G, Coonfield ML, Ross CA, et al. Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model. Neurosci Lett 2001;315:149–153.
170. Kieburtz K. Antiglutamate therapies in Huntington's disease. J Neural Transm 1999; Suppl 55:97–102.
171. Group HS. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 2001;57:397–404.
172. Beal M. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann Neurol 1992;31:119–130.
173. Beal MF, Hyman BT, Koroshetz W. Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases? Trends Neurosci 1993;16:125–131.
174. Albin R, Greenamyre J. Alternative excitotoxic hypotheses. Neurology 1992;42:733–738.
175. Beal MF. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol 1995;38:357–366.
176. Browne SE, Bowling AC
, MacGarvey U, et al. Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia. Ann Neurol 1997;41:646–653.
177. Parker WJ, Boyson SJ, Luder AS, et al. Evidence for a defect in NADH: Ubiquinone oxidoreductase (complex I) in Huntington's disease. Neurology 1990;40:1231–1234.
178. Arenas J, Campos Y, Ribacoba R, et al. Complex I defect in muscle from patients with Huntington's disease. Ann Neurol 1998;43:397–400.
179. Brennan WA Jr, Bird ED, Aprille JR. Regional mitochondrial respiratory activity in Huntington's disease brain. J Neurochem 1985;44:1948–1950.
180. Browne SE, Ferrante RJ, Beal MF. Oxidative stress in Huntington's disease. Brain Pathol 1999;9:147–163.
181. Jenkins B, Koroshetz W, Beal M, et al. Localized proton-NMR spectroscopy in patients with Huntington's disease (HD) demonstrates abnormal lactate levels in occipital cortex: Evidence for compromised metabolism in HD. Neurology 1992;42:223–229.
182. Panov AV, Burke JR, Strittmatter WJ, et al. In vitro effects of polyglutamine tracts on Ca2+-dependent depolarization of rat and human mitochondria: Relevance to Huntington's disease. Arch Biochem Biophys 2003;410:1–6.
183. Panov AV, Gutekunst CA, Leavitt BR, et al. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat Neurosci 2002;5:731–736.
184. Gines S, Seong IS, Fossale E, et al. Specific progressive cAMP reduction implicates energy deficit in presymptomatic Hunting-ton's disease knock-in mice. Hum Mol Genet 2003;12:497–508.
185. Novelli A, Reilly J, Lysko P, et al. Glutamate becomes neurotoxic via the N-methyl-d-aspartate receptor when intracellular energy levels are reduced. Brain Res 1988;451:205–212.
186. Greene J, Porter R, Eller R, et al. Inhibition of succinate dehydrogenase by malonic acid produces an “excitotoxic” lesion in rat striatum. J Neurochem 1993;61:1151–1154.
187. Beal MF, Brouillet E, Jenkins B, et al. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 1993;13:4181–4192.
188. Brouillet E, Hantraye P, Ferrante RJ, et al. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc Natl Acad Sci U S A 1995;92:7105–7109.
189. Greene J, Greenamyre J: Characterization of the excitotoxic potential of the reversible succinate dehydrogenase inhibitor malonate. J Neurochem 64:430–436, 1995.
190. Beal M, Henshaw D, Jenkins B, et al. Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate. Ann Neurol 36:882–888.
191. Henshaw R, Jenkins B, Schulz J, et al. Malonate produces striatal lesions by indirect NMDA receptor activation. Brain Res 1994;647:161–166.
192. Huntington Study Group. Safety and tolerability of the free-radical scavenger OPC-14117 in Huntington's disease. Neurology 1998;50:1366–1373.
193. Ferrante RJ, Andreassen OA, Jenkins BG, et al. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J Neurosci 2000;20:4389–4397.
194. Hersch SM, Gevorkian S, Marder K, et al. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology 2006;66:250–252.
195. Stack EC
, Matson WR, and Ferrante RJ. Evidence of oxidant damage in Huntington's disease: Translational strategies using antioxidants. Ann N Y Acad Sci 2008;1147:79–92.
196. Tellez-Nagel I, Johnson AB, and Terry RD. Studies on brain biopsies of patients with Huntington's chorea. J Neuropathol Exp Neurol 1974;33(2):308–332.
197. Browne SE, Ferrante RJ, and Beal MF. Oxidative stress in Huntington's disease. Brain Pathol 1999;9(1):147–163.
198. Butterworth NJ, Williams L, Bullock JY, et al. Trinucleotide (CAG) repeat length is positively correlated with the degree of DNA fragmentation in Huntington's disease striatum. Neuroscience 1998;87(1):49–53.
199. Polidori MC, Mecocci P, Browne SE, et al. Oxidative damage to mitochondrial DNA in Huntington's disease parietal cortex. Neurosci Lett 1999; 272(1):53–56.
200. Kovtun IV, Liu Y, Bjoras M, et al. OGG1 initiates age-dependent CAG trinucleotide expansion in somatic cells. Nature 2007;447(7143):447–452.
201. Stoy N, Mackay GM, Forrest CM, et al. Tryptophan
metabolism and oxidative stress in patients with Huntington's disease. J Neurochem 2005;93(3):611–623.
202. Jenkins BG, Koroshetz WJ, Beal MF, et al. Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy. Neurology 1993;43:2689–2695.
203. Lodi R, Schapira AH, Manners D, et al. Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Ann Neurol 2000;48:72–76.
204. Hengartner MO. The biochemistry of apoptosis. Nature 2000;407:770–776.
205. Friedlander RM. Apoptosis and caspases in neurodegenerative diseases. N Engl J Med 2003; 348:1365–1375.
206. Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72:971–983.
207. Li SH, Schilling G, Young WS, et al. Huntington's disease gene (IT15) is widely expressed in human and rat tissues. Neuron 1993;11:985–993.
208. Strong TV, Tagle DA, Valdes JM, et al. Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues. Nat Genet 1993;5:259–265.
209. Ambrose CM, Duyao MP, Barnes G, et al. Structure and expression of the Huntington's disease gene: Evidence against simple inactivation due to an expanded CAG repeat. Somat Cell Mol Genet 1994;20:27–38.
210. Duyao MP, Auerbach AB, Ryan A, et al. Inactivation of the mouse Huntington's disease gene homolog Hdh. Science 1995;269:407–410.
211. Nasir J, Floresco SB, O'Kusky JR, et al. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 81:811–823.
212. Landwehrmeyer GB, McNeil SM, Dure LS, et al. Huntington's disease gene: Regional and cellular expression in brain of normal and affected individuals. Ann Neurol 1995;37:218–230.
213. Eberwine J, McLaughlin B. Striatal RNA-binding proteins interact with huntingtin mRNA. In Ariano M, Surmeier D (eds). Molecular and Cellular Mechanisms of Neostriatal Function. Austin: RG Landes, 1995, pp. 143–149.
214. Johnson R, Zuccato C, Belyaev D, et al. A microRNA-based gene dysregulation pathway in Huntington's disease. Neurobiol Dis 2008;29(3):438–445.
215. Savas JN, Makusky A, Ottosen S, et al. Huntington's disease protein contributes to RNA-mediated gene silencing through association with Argonaute and P bodies. Proc Natl Acad Sci U S A 2008;105(31):10820–10825.
216. DiFiglia M, Sapp E, Chase K, et al. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron 1995;14:1075–1081.
217. Hoogeveen AT, Willemsen R, Meyer N, et al. Characterization and localization of the Huntington disease gene product. Hum Mol Genet 1993;2:2069–2073.
218. Gutekunst CA, Levey AI, Heilman CJ, et al. Identification and localization of huntingtin in brain and human lymphoblastoid cell lines with anti-fusion protein antibodies. Proc Natl Acad Sci U S A 1995;92:8710–8714.
219. Sharp AH, Loev SJ, Schilling G, et al. Widespread expression of Huntington's disease gene (IT15) protein product. Neuron 1995;14:1065–1074.
220. Trottier Y, Devys D, Imbert G, et al. Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form. Nat Genet 1995;10:104–110.
221. Ferrante R, Gutekunst C-A, Persichetti F, et al. Heterogeneous topographic and cellular distribution of huntingtin expression in the normal human neostriatum. J Neurosci 1997;17:3052–3063.
222. Gutekunst CA, Li SH, Yi H, et al. The cellular and subcellular localization of huntingtin-associated protein 1 (HAP1): Comparison with huntingtin in rat and human. J Neurosci 1998;18:7674–7686.
223. Kegel KB, Kim M, Sapp E, et al. Huntingtin expression stimulates endosomal-lysosomal activity, endosome tubulation, and autophagy. J Neurosci 2000;20:7268–7278.
224. Sieradzan KA, Mechan AO, Jones L, et al. Huntington's disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein. Exp Neurol 1999; 156(1):92–99.
225. Yanai A, Huang K, Kang R, et al. Palmitoylation of huntingtin by HIP14 is essential for its trafficking and function. Nat Neurosci 2006;9(6):824–831.
226. Jeong HF, Then TJ, Melia JR Jr, et al. Acetylation targets mutant huntingtin to autophagosomes for degradation. Cell 2009;137(1):60–72.
227. Steffan JS, Agrawal N, Pallos J, et al. SUMO modification of Huntingtin and Huntington's disease pathology. Science 2004;304(5667):100–104.
228. Humbert S, Bryson EA, Cordelieres FA, et al. The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Dev Cell 2002;2(6):831–837.
229. Zala DE, Colin H, Rangone G, et al. Phosphorylation of mutant huntingtin at S421 restores anterograde and retrograde transport in neurons. Hum Mol Genet 2008;17(24):3837–3846.
230. Thompson LM, Aiken CL, Kaltenbach LS, et al. IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. J Cell Biol 2009.
231. Aiken CT, Steffan JS, Guerrero CM, et al. Phosphorylation of threonine 3: Implications for Huntingtin aggregation and neurotoxicity. J Biol Chem 2009;284(43):29427–29436.
232. Rigamonti D, Bauer JH, De-Fraja C, et al. Wild-type huntingtin protects from apoptosis upstream of caspase-3. J Neurosci 2000;20:3705–3713.
233. Leavitt BR, Guttman JA, Hodgson JG, et al. Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo. Am J Hum Genet 2001;68:313–324.
234. Ho LW, Brown R, Maxwell M, et al. Wild type huntingtin reduces the cellular toxicity of mutant huntingtin in mammalian cell models of Huntington's disease. J Med Genet 2001;38:450–452.
235. Li SH and Li XJ. Aggregation of N-terminal huntingtin is dependent on the length of its glutamine
repeats. Hum Mol Genet 1998;7:777–782.
236. Trottier Y, Lutz Y, Stevanin G, et al. Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias. Nature 1995;378:403–406.
237. Perutz MF, Johnson T, Suzuki M, et al. Glutamine
repeats as polar zippers: Their possible role in inherited neurodegenerative diseases. Proc Natl Acad Sci U S A 1994;91:5355–5358.
238. Maat-Schieman ML, Dorsman JC, Smoor MA, et al. Distribution of inclusions in neuronal nuclei and dystrophic neurites in Huntington disease brain. J Neuropathol Exp Neurol 1999;58:129–137.
239. Scherzinger E, Lurz R, Turmaine M, et al. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 1997;90:549–558.
240. Martindale D, Hackam A, Wieczorek A, et al. Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates. Nat Genet 1998;18:150–154.
241. Becher MW, Kotzuk JA, Sharp AH, et al. Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: Correlation between the density of inclusions and IT15 CAG triplet repeat length. Neurobiol Dis 1998;4:387–397.
242. Skinner P, Koshy B, Cummings C, et al. Ataxin-1 with an expanded glutamine
tract alters nuclear matrix-associated structures. Nature 1997;389:971–974.
243. Paulson H, Perez M, Trottier Y, et al. Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron 1997;19:333–344.
244. Holmberg M, Duyckaerts C, Durr A, et al. Spinocerebellar ataxia type 7 (SCA7): A neurodegenerative disorder with neuronal intranuclear inclusions. Hum Mol Genet 1998;7:913–918.
245. Li M, Miwa S, Kobayashi Y, et al. Nuclear inclusions of the androgen receptor protein in spinal and bulbar muscular atrophy. Ann Neurol 1998;44:249–254.
246. Ross CA. Intranuclear neuronal inclusions: A common pathogenic mechanism for glutamine-repeat neurodegenerative diseases? Neuron 1997;19:1147–1150.
247. Davies SW, Beardsall, K, Turmaine M, et al. Are neuronal intranuclear inclusions the common neuropathology of triplet-repeat disorders with polyglutamine-repeat expansions? Lancet 1998;351:131–133.
248. Kuemmerle S, Gutekunst CA, Klein AM, et al. Huntington aggregates may not predict neuronal death in Huntington's disease. Ann Neurol 1999;46:842–849.
249. Davies SW, Turmaine M, Cozens BA, et al. Formation of neuronal intranuclear inclusions underlies the neurological dys-function in mice transgenic for the HD mutation. Cell 1997;90:537–548.
250. Ordway J, Tallaksen-Greene S, Gutekunst C-A, et al. Ectopically expressed CAG repeats cause intranuclear inclusions and a progressive late onset neurological phenotype in the mouse. Cell 1997;91:753–763.
251. Saudou F, Finkbeiner S, Devys D, et al. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 1998;95:55–66.
252. Chun W, Lesort M, Lee M, et al. Mutant huntingtin aggregates do not sensitize cells to apoptotic stressors. FEBS Lett 2002;515:61–65.
253. Kim M, Lee HS, LaForet G, et al. Mutant huntingtin expression in clonal striatal cells: Dissociation of inclusion formation and neuronal survival by caspase inhibition. J Neurosci 1999;19:964–973.
254. Klement I, Skinner P, Kaytor M, et al. Ataxin-1 nuclear localization and aggregation: Role in polyglutamine-induced disease in SCA1 transgenic mice. Cell 1998;95:41–53.
255. Kuemmerle S, Gutekunst CA, Klein AM, et al. Huntington aggregates may not predict neuronal death in Huntington's disease. Ann Neurol 1999;46(6):842–849.
256. Arrasate M, Mitra S, Schweitzer ES, et al. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 2004;431(7010):805–810.
257. Taylor JP, Tanaka F, Robitschek J et al. Aggresomes protect cells by enhancing the degradation of toxic polyglutamine-containing protein. Hum. Mol. Genet 2003;12:749–757)
258. Chen S, Berthelier V, Yang W, et al. Polyglutamine aggregation behavior in vitro supports a recruitment mechanism of cytotoxicity. J Mol Biol 2001;311:173–182.
259. Poirier MA, Li H, Macosko J, et al. Huntingtin spheroids and protofibrils as precursors in polyglutamine fibrilization. J Biol Chem 2002;277:41032–41037.
260. Hodgson J, Agopyan N, Gutekunst C-A, et al. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 1999;23:181–192.
261. Kaltenbach LS, Romero E, Becklin R, et al. Huntingtin interacting proteins are genetic modifiers of neurodegeneration. PLoS Genet 2007;3(5):e82.
262. Li XJ, Li SH, Sharp AH, et al. A huntingtin-associated protein enriched in brain with implications for pathology. Nature 1995;378:398–402.
263. Li Y, Chin LS, Levey AI, et al. Huntingtin-associated protein 1 interacts with hepatocyte growth factor-regulated tyrosine kinase substrate and functions in endosomal trafficking. J Biol Chem 2002;277:28212–28221.
264. Li SH, Gutekunst CA, Hersch SM, et al. Interaction of huntingtin-associated protein with dynactin P150Glued. J Neurosci 1998;18:1261–1269.
265. Sittler A, Walter S, Wedemeyer N, et al. SH3GL3 associates with the Huntingtin exon 1 protein and promotes the formation of polygln-containing protein aggregates. Mol Cell 1998;2:427–436.
266. Kalchman M, Koide H, McCutcheon K, et al. HIP1, a human homolog of S. cerevisiae Sla2p, interacts with membrane associated huntingtin in the brain. Nat Genet 1997;16:44–53.
267. Wanker EE, Rovira C, Scherzinger E, et al. HIP-I: A huntingtin interacting protein isolated by the yeast two-hybrid system. Hum Mol Genet 1997;6:487–495.
268. Metzler M, Legendre-Guillemin V, Gan L, et al. HIP1 functions in clathrin-mediated endocytosis through binding to clathrin and adaptor protein 2. J Biol Chem 2001;276:39271–39276.
269. Singaraja RR, Hadano S, Metzler M, et al. HIP14, a novel ankyrin domain-containing protein, links huntingtin to intracellular trafficking and endocytosis. Hum Mol Genet 2002;11:2815–2828.
270. Burke, JR, Enghild JJ, Martin ME, et al. Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH. Nat Med 1996;2:347–350.
271. Bao J, Sharp AH, Wagster MV, et al. Expansion of polyglutamine repeat in huntingtin leads to abnormal protein interactions involving calmodulin. Proc Natl Acad Sci U S A 1996;93:5037–5042.
272. Holbert S, Dedeoglu A, Humbert S, et al. Cdc42-interacting protein 4 binds to huntingtin: Neuropathologic and biological evidence for a role in Huntington's disease. Proc Natl Acad Sci U S A 2003;100:2712–2717.
273. Gerber H-P, Seipel K, Georgiev O, et al. Transcriptional activation modulated by homopolymeric glutamine
and proline stretches. Science 1994;263:808–811.
274. Passani LA, Bedford MT, Faber PW, et al. Huntingtin's WW domain partners in Huntington's disease post-mortem brain fulfill genetic criteria for direct involvement in Huntington's disease pathogenesis. Hum Mol Genet 2000;9:2175–2182.
275. Boutell JM, Thomas P, Neal JW, et al. Aberrant interactions of transcriptional repressor proteins with the Huntington's disease gene product, huntingtin. Hum Mol Genet 1999;8:1647–1655.
276. Steffan JS, Kazantsev A, Spasic-Boskovic O, et al. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci U S A 2000;97:6763–6768.
277. Li SH, Cheng AL, Zhou H, et al. Interaction of Huntington disease protein with transcriptional activator Sp1. Mol Cell Biol 2002;22:1277–1287.
278. Holbert S, Denghien I, Kiechle T, et al. The Gln-Ala repeat transcriptional activator CA150 interacts with huntingtin: Neuropathologic and genetic evidence for a role in Huntington's disease pathogenesis. Proc Natl Acad Sci U S A 2001;98:1811–1816.
279. Dunah AW, Jeong H, Griffin A, et al. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 2002;296:2238–2243.
280. Cha JH. Transcriptional dysregulation in Huntington's disease. Trends Neurosci 2000;23:387–392.
281. Stack EC
, Del Signore SJ, Luthi-Carter R, et al. Modulation of nucleosome dynamics in Huntington's disease. Hum Mol Genet 2007;16(10):1164–1175.
282. Sadri-Vakili G and J.H. Cha, Mechanisms of disease: Histone modifications in Huntington's disease. Nat Clin Pract Neurol 2006;2(6):330–338.
283. Sadri-Vakili G, Bouzou B, Benn CL, et al. Yohrling, and J.H. Cha. Histones associated with downregulated genes are hypo-acetylated in Huntington's disease models. Hum Mol Genet 2007;16(11):1293–1306.
284. Benn CL, Sun T, Sadri-Vakili G, et al. Huntingtin modulates transcription, occupies gene promoters in vivo, and binds directly to DNA in a polyglutamine-dependent manner. J Neurosci 2008;28(42):10720–12733.
285. Kalchman MA, Graham RK, Xia G, et al. Huntingtin is ubiquitinated and interacts with a specific ubiquitin-conjugating enzyme. J Biol Chem 1996;271:19385–19394.
286. Cooper AJ, Jeitner TM, Gentile V, et al. Cross linking of polyglutamine domains catalyzed by tissue transglutaminase is greatly favored with pathological-length repeats: Does transglutaminase activity play a role in (CAG)(n)/Q(n)-expansion diseases? Neurochem Int 2002;40:53–67.
287. Goldberg YP, Nicholson DW, Rasper DM, et al. Cleavage of huntingtin by apopain, a proapoptotic cysteine
protease, is modulated by the polyglutamine tract. Nat Genet 1996;13:442–449.